ClinicalTrials.gg
CompletedNCT04008186Updated May 30, 2025

A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone

A Phase 1 interventional study of Omaveloxolone and Midazolam oral solution in Healthy Adult Subjects, sponsored by Biogen. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-30.

Sponsored by Biogen · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2019, 7 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
61
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will assess the potential for clinical drug-drug interactions between omaveloxolone and a number of substrates and inhibitors of metabolic enzymes and drug transporters.

02

Conditions studied

  • Healthy Adult Subjects

Keywords

  • RTA 408
  • RTA 408 capsules
  • omaveloxolone
  • omaveloxolone capsules
  • DDI
03

In context

Lead sponsor

Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.

Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must satisfy all of the following criteria at the Screening Visit unless otherwise stated:

  • Males or females, of any race, between 18 and 55 years of age, inclusive.
  • between 18.0 and 32.0 kg/m2, inclusive, and a total body weight >50 kg.
  • In good health.
  • Females will not be pregnant or lactating, and females of and males will agree to use .
  • Able to comprehend and willing to sign an ICF and to abide by the study restrictions.

Exclusion criteria

Exclusion Criteria:

Subjects will be excluded from the study if they satisfy any of the following criteria at the Screening visit, unless otherwise stated:

  • Significant history or clinical manifestation of any major system disorder, as determined by the investigator (or designee).
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator (or designee).
  • History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (cholecystectomy will not be allowed; uncomplicated appendectomy and hernia repair will be allowed).
  • History of alcoholism or drug/chemical abuse within 2 years prior to Check in (Day 1).
  • Abnormal laboratory values considered by the investigator
  • Clinically significant abnormal 12 lead ECGs
  • Personal history of unexplained syncopal events, or family history of long syndrome or sudden unexplained death in a young person.
  • Pulse rate \<50 bpm or systolic blood pressure \<110 mmHg.
  • Alcohol consumption of >21 units per week for males and >14 units for females.
  • Positive urine drug screen or positive alcohol breath test result or positive urine drug screen.
  • Positive hepatitis panel and/or positive test. Participation in a clinical study involving administration of an drug (new chemical entity) in the past 30 days prior to dosing or 5 half lives (if known), whichever is longer, prior to dosing.
  • Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to dosing, unless deemed acceptable by the investigator (or designee).
  • Have previously completed or withdrawn from this study or any other study investigating omaveloxolone, and have previously received the investigational product.
  • Subjects who, in the opinion of the investigator (or designee), should not participate in this study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Omaveloxolone and Multiple Drugs (Part 1)

    Single oral doses of 2 mg midazolam, 1 mg repaglinide, 500 mg metformin, and a 10 mg rosuvastatin/0.25 mg digoxin cocktail on Days 1, 2, 3, and 5, respectively, and 18, 19, 20, and 22, respectively. Oral doses of 150 mg omaveloxolone on Days 12 to 27

    Drug: Omaveloxolone · Drug: Midazolam oral solution · Drug: Repaglinide 1 MG · Drug: MetFORMIN 500 Mg Oral Tablet · Drug: Rosuvastatin · Drug: Digoxin tablet

  • Experimental
    Omaveloxolone & Gemfibrozil (Part 2)

    Single oral doses of 150 mg omaveloxolone on Days 1 and 13. Oral doses of 600 mg gemfibrozil (twice daily) on Days 10 to 18

    Drug: Omaveloxolone · Drug: Gemfibrozil Tablets

  • Experimental
    Omaveloxolone and Itraconazole (Part 3)

    Single oral doses of 150 mg omaveloxolone on Days 1 and 13. Oral doses of 200 mg itraconazole on Days 10 to 18.

    Drug: Omaveloxolone · Drug: Itraconazole capsule

  • Experimental
    Omaveloxolone and Verapamil (Part 4)

    Single oral doses of 150 mg omaveloxolone on Days 1 and 13. Oral doses of 120 mg verapamil on Days 10 to 18.

    Drug: Omaveloxolone · Drug: Verapamil Pill

Interventions

  • 50 mg capsules

    Also known as: RTA 408

  • DrugMidazolam oral solution

    2 mg/mL oral solution

  • 1 mg tablet

  • DrugMetFORMIN 500 Mg Oral Tablet

    500 mg tablet

  • DrugRosuvastatin

    10 mg tablet

  • DrugDigoxin tablet

    0.25 mg tablet

  • DrugGemfibrozil Tablets

    600 mg tablet

  • DrugItraconazole capsule

    100 mg capsule

  • DrugVerapamil Pill

    120 mg tablet

06

What researchers measure

Primary outcomes

  1. Part 1 - Maximum concentration (Cmax) of probe drugs co-administered with omaveloxolone (midazolam, repaglinide, metformin, rosuvastatin, and digoxin)

    Pharmacokinetics will be assessed by blood sampling for midazolam, repaglinide, metformin, rosuvastatin, and digoxin to determine maximum observed concentration (Cmax).

    Time frame: 28 days

  2. Part 1 - Area under the plasma concentration-time curve of (AUC) for probe drugs co-administered with omaveloxolone (midazolam, repaglinide, metformin, rosuvastatin, and digoxin)

    Pharmacokinetics will be assessed by blood sampling for midazolam, repaglinide, metformin, rosuvastatin, and digoxin to determine area under the curve (AUC).

    Time frame: 28 days

  3. Part 2 - Maximum concentration (Cmax) of omaveloxolone

    Pharmacokinetics will be assessed by blood sampling for omaveloxolone to determine maximum observed concentration (Cmax).

    Time frame: 23 days

  4. Part 2 - Area under the omaveloxolone concentration-time curve (AUC)

    Pharmacokinetics will be assessed by blood sampling for omaveloxolone to determine area under the curve (AUC).

    Time frame: 23 days

  5. Part 3 - Maximum concentration (Cmax) of omaveloxolone

    Pharmacokinetics will be assessed by blood sampling for omaveloxolone to determine maximum observed concentration (Cmax).

    Time frame: 23 days

  6. Part 3 - Area under the omaveloxolone concentration-time curve (AUC)

    Pharmacokinetics will be assessed by blood sampling for omaveloxolone to determine area under the curve (AUC).

    Time frame: 28 days

  7. Part 4 - Maximum concentration (Cmax) of omaveloxolone

    Pharmacokinetics will be assessed by blood sampling for omaveloxolone to determine maximum observed concentration (Cmax).

    Time frame: 23 days

  8. Part 4 - Area under the omaveloxolone concentration-time curve (AUC)

    Pharmacokinetics will be assessed by blood sampling for omaveloxolone to determine area under the curve (AUC).

    Time frame: 28 days

07

Study locations

1 site
  • Covance Clinical Research Unit (CRU) Inc.
    Dallas, Texas 75247, United States
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Aug 2019, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2019
First posted
Jul 5, 2019
StartActual
Jun 14, 2019
Primary completionActual
Aug 18, 2019
CompletionActual
Aug 28, 2019
Last update
May 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04008186
Lead sponsor
Biogen
Collaborators
Covance
Responsible party
Sponsor
First posted
Jul 5, 2019
Start date
Jun 14, 2019
Primary completion
Aug 18, 2019
Completion
Aug 28, 2019
Last update
May 30, 2025

Study contacts

Jennifer Zon, MD
principal investigator · Covance CRU Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omaveloxolone

Start the discussion